Endometriosis is a chronic, inflammatory disease affecting over 200 million women worldwide—more than 10% of women of reproductive age. It occurs when uterine lining cells (endometrial cells) relocate and grow outside the uterus, leading to a pathological phenomenon that triggers severe pain, heavy bleeding, and is associated with infertility. The condition profoundly disrupts nearly every aspect of life, including education, careers, relationships, and family planning. Despite its prevalence, endometriosis remains underdiagnosed, misunderstood, and often dismissed as “just bad cramps,” contributing to significant delays in treatment.
The Challenges of Diagnosis
The journey to a diagnosis is one of the most frustrating aspects of endometriosis. Women endure an average delay of 4 to 15 years before receiving an accurate diagnosis, suffering in silence during this time. The lack of awareness among both patients and healthcare providers often leads to misdiagnoses, with symptoms being attributed to other conditions such as irritable bowel syndrome (IBS) or pelvic inflammatory disease (PID). This prolonged uncertainty takes a heavy toll on physical and emotional well-being, leaving many women feeling isolated and misunderstood.
Even after diagnosis, treatment options for endometriosis remain frustratingly limited. The most commonly prescribed therapies are hormonal treatments, which suppress symptoms but also disrupt natural hormonal balance, making them unsuitable for women trying to conceive. For many, the alternative is invasive surgery to remove endometrial growths, but this approach is not always effective and often comes with significant risks. Despite advances in medical science, there is still no definitive cure, leaving millions of women reliant on temporary and often ineffective solutions. The need for a novel, non-hormonal therapy that addresses the root causes of endometriosis has never been more urgent.
Foraviset